Relay Therapeutics, Inc. – NASDAQ:RLAY

Add to watchlist

$3.4

-0.96

-22.02%

Market closed

Open in about 5 hours

-47.09%

month

-47.09%

quarter

-61.75%

year

Market Cap	698.82M
Enterprise value	1.92B

P/E	-6.67
EV/Sales	1396.37
EV/EBITDA	-6.84
Price/Sales	1464.48
Price/Book	2.12
PEG ratio	-0.19
EPS	-2.65

Revenue	35.32M
EBITDA	-368.35M
Income	-329.12M
Revenue Q/Q	4327.87%
Revenue Y/Y	2873.65%

Profit margin	-21036.13%
Oper. margin	-21670.89%
Gross margin	26.43%
EBIT margin	-21670.89%
EBITDA margin	-1042.69%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Relay Therapeutics, Inc. (NASDAQ:RLAY): Profit margin
Jun 2023	119K	-98.50M	-82777.31%
Sep 2023	25.20M	-65.73M	-260.83%
Dec 2023	-1K	-83.49M	8349500%
Mar 2024	10.00M	-81.38M	-813.3%

Relay Therapeutics Financials Estimate

Q Y

Relay Therapeutics, Inc. (NASDAQ:RLAY): Analyst Estimates
Dec 2023	-1K	-83.49M	8349500%
Mar 2024	10.00M	-81.38M	-813.3%
Oct 2025	50K	-95.51M	-191030.8%
Dec 2025	50K	-96.16M	-192339.23%

Analysts Price target
Financials & Ratios estimates

Relay Therapeutics, Inc. (NASDAQ:RLAY): Debt to assets
Jun 2023	962016000	151.89M	15.79%
Sep 2023	906959000	128.58M	14.18%
Dec 2023	843980000	91.97M	10.9%
Mar 2024	841441000	95.67M	11.37%

Relay Therapeutics, Inc. (NASDAQ:RLAY): Cash Flow
Jun 2023	-68.60M	51.27M	2.08M
Sep 2023	-75.39M	71.36M	9.45M
Dec 2023	-89.18M	59.67M	21.91M
Mar 2024	-50.32M	10.53M	48.92M

Relay Therapeutics alternative data

Relay Therapeutics, Inc. (NASDAQ:RLAY): Employee count
Aug 2023	328
Sep 2023	345
Oct 2023	345
Nov 2023	345
Dec 2023	343
Jan 2024	343
Feb 2024	343
Mar 2024	323
Apr 2024	323
May 2024	323
Jun 2024	309
Jul 2024	309

Relay Therapeutics
Hedge Funds Holdings Q1 2023

35.69% -64.31%

of RLAY is owned by hedge funds

89 -73

hedge funds hold RLAY stock

40.06M -88.03M

shares is hold by hedge funds

RLAY hedge funds holdings changes

Relay Therapeutics
Insider Trading

Relay Therapeutics, Inc. (NASDAQ:RLAY): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	8763
Mar 2024	0	1759
Apr 2024	0	7349
Jun 2024	0	91470
Dec 2024	0	100000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	16 Dec 2024	PATEL SANJIV director, officer: President and CEO director, officer: President an..	Common Stock	100,000	$5	$500,000
Sale	27 Jun 2024	BERGSTROM DONALD A officer: Presiden..	Common Stock	648	$6.26	$4,056
Sale	27 Jun 2024	RAHMER PETER officer: See remarks officer: See remarks	Common Stock	245	$6.26	$1,534
Sale	27 Jun 2024	CATINAZZO THOMAS officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	295	$6.26	$1,847
Sale	27 Jun 2024	CATINAZZO THOMAS officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	9,078	$6.24	$56,647
Sale	27 Jun 2024	ADAMS BRIAN officer: Chief Le..	Common Stock	295	$6.26	$1,847
Option	10 Jun 2024	RUBIN JAMI director director	Common Stock	42,242	$5.04	$212,900
Option	10 Jun 2024	RUBIN JAMI director director	Stock Option (Right to Buy)	42,242	$5.04	$212,900
Sale	5 Jun 2024	RAHMER PETER officer: See remarks officer: See remarks	Common Stock	20,450	$7.06	$144,377
Sale	4 Jun 2024	RAHMER PETER officer: See remarks officer: See remarks	Common Stock	40,595	$6.64	$269,551

RLAY insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application FGFR INHIBITORS AND METHODS OF MAKING AND USING THE SAME Filling date: 18 Nov 2021 Issue date: 23 Jun 2022	18 Nov 2021	23 Jun 2022
Application	Application SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME Filling date: 23 Sep 2020 Issue date: 25 Mar 2021	23 Sep 2020	25 Mar 2021
Application	Application PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Filling date: 21 Mar 2019 Issue date: 11 Mar 2021	21 Mar 2019	11 Mar 2021
Application	Application SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Filling date: 21 Feb 2019 Issue date: 17 Dec 2020	21 Feb 2019	17 Dec 2020
Application	Application PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS Filling date: 28 Sep 2018 Issue date: 13 Aug 2020	28 Sep 2018	13 Aug 2020
Application	Application PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS Filling date: 25 May 2018 Issue date: 4 Jun 2020	25 May 2018	4 Jun 2020
Application	Application SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Filling date: 24 Oct 2017 Issue date: 27 Feb 2020	24 Oct 2017	27 Feb 2020
Application	Application SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Filling date: 22 Sep 2017 Issue date: 10 Oct 2019	22 Sep 2017	10 Oct 2019

Relay Therapeutics
Executives

Insider	Age	Compensation
Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A. (1974) Chief Executive Officer, Pres & Director	51	$987,190
Dr. Donald A. Bergstrom M.D., Ph.D. (1972) Executive Vice President and Head of R&D	53	$669,820
Mr. Brian R. Adams J.D. (1974) Gen. Counsel & Sec.	51	$568,050
Dr. Mark Murcko Ph.D. (1960) Co-Founder & Director	65	$181,000
Mr. Alexis A. Borisy A.M. (1972) Co-Founder & Independent Chairman	53	$55,620

Relay Therapeutics
Latest News

Friday, 20 December 2024
13:01	Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade	zacks.com
Wednesday, 11 December 2024
06:00	Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival	globenewswire.com
Monday, 9 December 2024
16:05	Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium	globenewswire.com
Friday, 6 December 2024
10:35	After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)	zacks.com
Tuesday, 3 December 2024
08:01	Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors	globenewswire.com
08:00	Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors	globenewswire.com
Wednesday, 20 November 2024
10:35	Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround	zacks.com
Tuesday, 19 November 2024
10:35	Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround	zacks.com
Wednesday, 6 November 2024
16:05	Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights	globenewswire.com
Wednesday, 30 October 2024
16:05	Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024	globenewswire.com
Tuesday, 17 September 2024
09:26	Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?	zacks.com
Monday, 16 September 2024
16:57	Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion	seekingalpha.com
Wednesday, 11 September 2024
18:46	Why Relay Therapeutics Plummeted by Nearly 14% Today	fool.com
08:15	Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations	seekingalpha.com
08:06	GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session	benzinga.com
Tuesday, 10 September 2024
20:21	Relay Therapeutics Announces Pricing of Public Offering of Common Stock	globenewswire.com
14:50	Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market	benzinga.com
11:55	Relay Stock Soars on Upbeat Data From Breast Cancer Study	zacks.com
Monday, 9 September 2024
16:34	Relay Therapeutics Announces Proposed Public Offering of Common Stock	globenewswire.com
14:16	Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher	benzinga.com
11:30	Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients	benzinga.com
07:04	Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study	reuters.com
06:55	Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival	globenewswire.com
Friday, 6 September 2024
16:05	Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024	globenewswire.com
Tuesday, 6 August 2024
16:05	Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights	globenewswire.com
Thursday, 6 June 2024
07:00	Relay Therapeutics Discloses Three New Programs at New Program & Platform Event	globenewswire.com
Wednesday, 5 June 2024
16:05	Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608	globenewswire.com
Tuesday, 21 May 2024
16:05	Relay Therapeutics to Participate in Upcoming Investor Conferences	globenewswire.com
Monday, 13 May 2024
08:30	Relay Therapeutics to Host New Program and Platform Event on June 6, 2024	globenewswire.com
Thursday, 2 May 2024
18:41	Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 2 Aug 2025

Relay Therapeutics: What's Next For H2 2025?
Seeking Alpha 12 Apr 2025

Relay Therapeutics: Trying To Find That Right Price
Seeking Alpha 6 Nov 2023

Relay Therapeutics: Market Is Underestimating Lirafugratinib's Potential (Rating Upgrade)
Seeking Alpha 28 Jul 2023

Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608
Seeking Alpha 19 Jan 2023

Relay Therapeutics: Tall Claims, Some Proofs Of Concept, Some Concerns
Seeking Alpha 30 Oct 2022

Relay Therapeutics: Best-In-Class Potential PIKCA Mutation Inhibitor
Seeking Alpha 18 Sep 2022

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Frequently Asked Questions (FAQ)

What's the price of Relay Therapeutics stock today?

One share of Relay Therapeutics stock can currently be purchased for approximately $3.4.
When is Relay Therapeutics's next earnings date?

Unfortunately, Relay Therapeutics's (RLAY) next earnings date is currently unknown.
Does Relay Therapeutics pay dividends?

No, Relay Therapeutics does not pay dividends.
How much money does Relay Therapeutics make?

Relay Therapeutics has a market capitalization of 698.82M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1749.82% to 25.55M US dollars.
What is Relay Therapeutics's stock symbol?

Relay Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "RLAY".
What is Relay Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Relay Therapeutics?

Shares of Relay Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Relay Therapeutics's key executives?
Relay Therapeutics's management team includes the following people:
- Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A. Chief Executive Officer, Pres & Director(age: 51, pay: $987,190)
- Dr. Donald A. Bergstrom M.D., Ph.D. Executive Vice President and Head of R&D(age: 53, pay: $669,820)
- Mr. Brian R. Adams J.D. Gen. Counsel & Sec.(age: 51, pay: $568,050)
- Dr. Mark Murcko Ph.D. Co-Founder & Director(age: 65, pay: $181,000)
- Mr. Alexis A. Borisy A.M. Co-Founder & Independent Chairman(age: 53, pay: $55,620)
Is Relay Therapeutics founder-led company?

Yes, Relay Therapeutics is a company led by its founders Dr. Mark Murcko Ph.D. and Mr. Alexis A. Borisy A.M..
How many employees does Relay Therapeutics have?

As Jul 2024, Relay Therapeutics employs 309 workers, which is 4% less then previous quarter.
When Relay Therapeutics went public?

Relay Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 16 Jul 2020.
What is Relay Therapeutics's official website?

The official website for Relay Therapeutics is relaytx.com.
Where are Relay Therapeutics's headquarters?

Relay Therapeutics is headquartered at 399 Binney Street, Cambridge, MA.
How can i contact Relay Therapeutics?

Relay Therapeutics's mailing address is 399 Binney Street, Cambridge, MA and company can be reached via phone at +61 73708837.

Relay Therapeutics, Inc.

relaytx.com

Exchange:

NASDAQ

Full time employees:

294

Industry:

Biotechnology

Sector:

Healthcare

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

+61 73708837

399 Binney Street
Cambridge, MA 02139

CIK: 0001812364
ISIN: US75943R1023
CUSIP: 75943R102